Richard Peck
Fondateur chez Cellestia Biotech AG
Profil
Richard Peck is the founder of Cellestia Biotech AG, which was founded in 2014.
He held the title of Head-Regulatory Affairs at the company.
Dr. Peck's former job was as Head-Regulatory Affairs at Finox Biotech AG.
Postes actifs de Richard Peck
| Sociétés | Poste | Début |
|---|---|---|
Cellestia Biotech AG
 Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Fondateur | 01/01/2014 |
Anciens postes connus de Richard Peck
| Sociétés | Poste | Fin |
|---|---|---|
Finox Biotech AG
 Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | Conseiller Juridique Général | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Finox Biotech AG
Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | Health Services |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |